These results are consistent with previous works in BC where treatment with FASN inhibitors (EGCG and G28UCM) in combination with pertuzumab was able to resensitize lapatinib plus TZ-resistant cells to anti-HER2 drugs (Blancafort et al. 2015). This evidence concerns the gene ERBB2 and breast cancer.